Treatment
S-1 clinical trials
We’re tracking 792 recruiting studies that include S-1, each written for real people, not researchers, below.
Recruiting studies
- NCT06309485RecruitingPhase 2
Study of WGI-0301 for advanced liver cancer
This trial tests a new drug, WGI-0301, for people with advanced hepatocellular carcinoma (HCC, a type of liver cancer) that has progressed after standard treatments. It aims to see if WGI-0301 can help control the cancer when other options have stopped working or caused side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06315023Enrolling by invitation
A registry study for the DETOUR system
This study is collecting information from people who receive the DETOUR system, a treatment for blocked arteries. The goal is to see how well it works in real-world use.
Salinas, CaliforniaAges Any age - NCT06307054RecruitingPhase 1
CLL-1 CAR-NK cells for relapsed or refractory AML
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06295146Recruiting
Getting help from a peer coach to learn wheelchair skills
This study tests whether virtual one-on-one training with a peer who has a spinal cord injury can help you learn new wheelchair skills. You'll practice using video calls, and you need a helper nearby to keep you safe during practice.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06252402RecruitingEarly Phase 1
CAR T cells for HIV: A new immunotherapy study
This trial tests a new type of immune cell, called a CAR T cell, that is designed to target and kill cells infected with HIV. It may help control the virus without needing to take HIV medication all the time.
Duarte, CaliforniaAges 18 years+ - NCT06239727RecruitingPhase 3
Reduced-dose radiotherapy for stage III nasopharyngeal cancer based on response
This trial tests whether a lower dose of radiation can safely treat stage III nasopharyngeal cancer if you have already responded well to initial chemotherapy plus immunotherapy (Camrelizumab). The goal is to reduce side effects while still controlling the cancer.
Fuzhou, FujianAges 18–65 - NCT06214143RecruitingPhase 1/Phase 2
T3011 plus immunotherapy for advanced solid tumors
This trial tests a new drug combo (T3011 plus a PD-1/PD-L1 inhibitor) for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination can shrink tumors or slow their growth.
AnyangAges 18 years+ - NCT06199492Recruiting
Smart optical probe to guide cancer needle biopsies
This study tests a new optical probe that takes special images during a needle biopsy to help guide doctors to collect better samples. It may help people with cancer in lymph nodes, liver, or lung who are already scheduled for an image-guided biopsy.
Houston, TexasAges 18 years+ - NCT06165341RecruitingPhase 3
Fazirsiran for mild liver scarring in alpha-1 antitrypsin deficiency
This study tests an investigational drug called fazirsiran, which is designed to treat alpha-1 antitrypsin deficiency-related liver disease with mild scarring. The goal is to see if fazirsiran is safe and can improve or slow liver damage in people with the PiZZ genetic type.
Phoenix, ArizonaAges 18–75 - NCT06134492RecruitingPhase 3
Acyclovir for pneumonia patients with HSV-1 on breathing support
This trial tests whether acyclovir, an antiviral drug, can help patients with pneumonia who are on breathing support and have herpes simplex virus in their lung fluid. The goal is to see if it improves recovery.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT06119542Recruiting
GlycOrtho: Endothelial damage in major spine surgery
This study looks at how major spine surgery affects the inner lining of blood vessels. It measures a substance called syndecan-1 in the blood to understand this damage.
Bologna, BOAges 12–75 - NCT01851642Recruiting
Study how lung disease affects white blood cells
This study looks at how lung disease changes a type of blood cell called white blood cells. It may help researchers understand what’s happening in the lungs and how to better monitor or treat lung problems.
Gainesville, FloridaAges 18 years+ - NCT06051409RecruitingPhase 3
Olverembatinib for newly diagnosed Ph+ ALL
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
Birmingham, AlabamaAges 18 years+ - NCT05984147RecruitingPhase 1
Study of oral drug AUR108 for advanced lymphoma
This trial tests an experimental oral drug called AUR108 for people with advanced lymphoma that has come back after at least two prior treatments. The goal is to see if the drug is safe and if it can help shrink or control the lymphoma.
Visakhapatnam, Andhra PradeshAges 18–99 - NCT05973825Recruiting
HIV blood study to study immune responses over many years
This study looks at how the immune system and HIV behave in people on long-term HIV treatment (ART), using blood samples that will be stored for future tests for up to 20 years. It may help researchers understand how well treatment is controlling HIV and improve future care.
Ghent, Oost-VlaanderenAges 18–80 - NCT05960773RecruitingPhase 2
Oral medication for early mesothelioma in BAP1 gene carriers
This study tests an oral medication called decitabine/cedazuridine (INQOVI) that may help delay or prevent progression in people with early-stage mesothelioma who carry a BAP1 mutation. The treatment is given as a pill and aims to reactivate genes that may help control cancer growth.
Bethesda, MarylandAges 18–120 - NCT05886439RecruitingPhase 1/Phase 2
Study drug plus PD-1 or PD-L1 for lung cancer
This Phase 1/2 trial tests a new treatment called LK101 combined with a PD-1 or PD-L1 antibody for advanced lung cancer. It may help shrink tumors and improve control of the disease, especially after prior anti–PD-1/PD-L1 treatment has stopped working.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Birmingham, AlabamaAges 18–60 - NCT05850234RecruitingPhase 1/Phase 2
Study drug for hard-to-treat multiple myeloma after prior treatments
This Phase 1/2 study tests AZD0120 in people with multiple myeloma that has come back or is not responding to treatment. It may help by targeting the myeloma cells after you’ve already tried several standard therapies.
Birmingham, AlabamaAges 18 years+ - NCT05862012RecruitingPhase 1
Test drug ISB 2001 in multiple myeloma patients who relapsed
This Phase 1 study tests ISB 2001, a new investigational treatment, in people with multiple myeloma that has come back or not responded to prior treatment. It mainly focuses on safety and whether the drug can be given effectively.
Palo Alto, CaliforniaAges 18 years+ - NCT05865002RecruitingPhase 1
Safety and drug test for AUR107 in advanced cancers
This early-phase study tests whether AUR107 is safe and may help shrink or control advanced solid tumors that have come back or progressed. You may be considered if standard treatments no longer work and you meet specific blood, organ, and health requirements.
Vijayawada, Andhra PradeshAges 18 years+ - NCT05287464Recruiting
Study for metastatic kidney cancer treatments combinations
This trial studies people with advanced (metastatic) kidney cancer who are starting a specific set of first-line treatment combinations (including drugs like nivolumab, pembrolizumab, or avelumab, paired with targeted medicines). It may help improve how these treatment plans work for different types of kidney cancer.
Province of Macerata, MacerataAges 18 years+ - NCT05837455RecruitingPhase 2
Biomarker-guided treatment for early breast cancer before surgery
This trial looks at whether using tumor test results (biomarkers) can help guide the best hormone treatment and chemotherapy before surgery. It focuses on people with stage II or III, ER-positive, HER2-negative breast cancer, with the goal of improving how well the tumor responds before it is removed.
St Louis, MissouriAges 18 years+ - NCT05807178Recruiting
Light treatment to stabilize sleep-wake rhythm in ICU delirium
This trial tests whether controlled bright light in the ICU can improve confusion and the sleep-wake rhythm in adults who develop delirium. If it works, it may help patients become more clear-minded sooner while they recover in intensive care.
BerlinAges 18 years+
Common questions
- Are there clinical trials studying S-1?
- Yes. Clin2 currently lists 792 recruiting studies that include S-1, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a S-1 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is S-1 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether S-1 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.